244 related articles for article (PubMed ID: 34704422)
1. Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.
Tang Y; Kong Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 50(4):514-523. PubMed ID: 34704422
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).
Das AM
Appl Clin Genet; 2017; 10():43-48. PubMed ID: 28769581
[TBL] [Abstract][Full Text] [Related]
3. [Screening for hereditary tyrosinemia and genotype analysis in newborns].
Tong F; Yang R; Liu C; Wu D; Zhang T; Huang X; Hong F; Qian G; Huang X; Zhou X; Shu Q; Zhao Z
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 48(4):459-464. PubMed ID: 31901053
[TBL] [Abstract][Full Text] [Related]
4. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky JM; Singh R; Ficicioglu C; van Karnebeek CDM; Grompe M; Mitchell G; Waisbren SE; Gucsavas-Calikoglu M; Wasserstein MP; Coakley K; Scott CR
Genet Med; 2017 Dec; 19(12):. PubMed ID: 28771246
[TBL] [Abstract][Full Text] [Related]
7. Type 1 tyrosinemia in Finland: a nationwide study.
Äärelä L; Hiltunen P; Soini T; Vuorela N; Huhtala H; Nevalainen PI; Heikinheimo M; Kivelä L; Kurppa K
Orphanet J Rare Dis; 2020 Oct; 15(1):281. PubMed ID: 33046095
[TBL] [Abstract][Full Text] [Related]
8. Current strategies for the treatment of hereditary tyrosinemia type I.
Ashorn M; Pitkänen S; Salo MK; Heikinheimo M
Paediatr Drugs; 2006; 8(1):47-54. PubMed ID: 16494511
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and treatment of hereditary tyrosinemia in Japan.
Nakamura K; Matsumoto S; Mitsubuchi H; Endo F
Pediatr Int; 2015; 57(1):37-40. PubMed ID: 25443793
[TBL] [Abstract][Full Text] [Related]
10. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of living donor liver transplantation in a Thai boy with hereditary tyrosinemia type I: a case report.
Jitraruch S; Treepongkaruna S; Teeraratkul S; Wattanasirichaigoon D; Leelaudomlipi S; Sornmayura P; Viengteerawat S; Sriphojanart S
J Med Assoc Thai; 2011 Oct; 94(10):1276-80. PubMed ID: 22145516
[TBL] [Abstract][Full Text] [Related]
12. Newborn Screening for Hereditary Tyrosinemia Type I in Québec: Update.
Giguère Y; Berthier MT
Adv Exp Med Biol; 2017; 959():139-146. PubMed ID: 28755192
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong.
Mak CM; Lam CW; Chim S; Siu TS; Ng KF; Tam S
Clin Biochem; 2013 Jan; 46(1-2):155-9. PubMed ID: 23000314
[TBL] [Abstract][Full Text] [Related]
14. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1-fetoprotein normalization.
Bhushan S; Noble C; Balouch F; Lewindon P; Lampe G; Hodgkinson P; McGill J; Ee L
Pediatr Transplant; 2022 Nov; 26(7):e14334. PubMed ID: 35698261
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review.
Geppert J; Stinton C; Freeman K; Fraser H; Clarke A; Johnson S; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Sep; 12(1):154. PubMed ID: 28893311
[TBL] [Abstract][Full Text] [Related]
17. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I.
Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD
Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105
[TBL] [Abstract][Full Text] [Related]
18. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
